

Saxenda® Dosing Guide

Initiating treatment with Saxenda® for chronic weight management

Saxenda® (liraglutide) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:¹

- 30 kg/m² or greater (obese), or
- 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia) and who have failed a previous weight management intervention.



Simple, once-daily dosing at any time of day, independent of meals¹

Patients should follow a progressive dose escalation to achieve the maintenance dose of 3.0 mg/day



- If patients do not tolerate an increased dose during dose escalation, each step in the dose escalation can be delayed up to 7 days
- If a patient has not lost at least 5% of their initial body weight after 12 weeks on the 3.0 mg maintenance dose, treatment with Saxenda® should be discontinued

Demonstrate the first injection in the office to help patients get started

1 attach needle



2 select dose



3 inject dose



count slowly
1-2-3-4-5-6

4 remove needle



The Saxenda® pen is designed to be used with NovoFine® Plus—the only 4 mm, universal pen needle with comfort-base technology so patients can experience a **virtually painless injection**.*

* Comparative clinical significance has not been established.

SaxendaCare® Patient Support Program

Encourage your patients to enrol in SaxendaCare®

A FREE patient support program to help patients on Saxenda® work towards their weight management goals.

Patients will receive access to:

- ✓ Resources to get them started with Saxenda®
- ✓ A guided program with regular check-ins via email
- ✓ Scientifically-validated behavioural strategies used by weight management experts to help them incorporate the right lifestyle changes

Patients can enrol by visiting www.SaxendaCare.ca

Consult the Product Monograph at http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxenda_PM_English.pdf for more information on conditions of clinical use, contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information. The Product Monograph is also available by calling Novo Nordisk at 1-800-465-4334.

Reference:

1. Saxenda® Product Monograph, Novo Nordisk Canada Inc., 2017.



Saxenda®, SaxendaCare® and NovoFine® Plus are registered trademarks of Novo Nordisk A/S and used under license by Novo Nordisk Canada Inc.
Novo Nordisk Canada Inc., Tel: (905) 629-4222 or 1-800-465-4334. www.novonordisk.ca
© Novo Nordisk Canada Inc. CA205X00008E

